Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Cabergoline in PCOS
NCT05981742Phase 2Completed
- Sponsor
- Al-Rasheed University College
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabergoline in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Al-Rasheed University College. Primary endpoints: Body Mass Index at 90 days, Serum Anti-Müllerian Hormone at 90 days and 9 more. Started Sep 2022; status: completed.
02
Drugs
cabergoline
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT05981742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981742.